CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...
Analysis by researchers at the University of Bern suggests that water and other volatile compounds arrived on Earth from ...
DNA folding is more important for cell function than previously thought, finding that even the most subtle changes in DNA’s ...
Technology Networks interviewed the Salk Institute's Professor Alan Saghatelian about his latest research using CRISPR-based ...
At WIRED Health 2025, Orchid CEO Noor Siddiqui and genomics pioneer George Church laid out their view of the future of ...
The placenta is a unique organ that exists only during pregnancy, growing at tumour-like speed to the size of a small dinner ...
MarketNewsUpdates News Commentary NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy ...
Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been ...
Zacks Investment Research on MSN
Vertex Plunges Around 24% in Six Months: How to Play the Stock
Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline ...
The esteemed scientist, one of the world’s leading experts in molecular biology, explains how disruptions at the cellular level influence health ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback